PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsFirst patient receives genome-editing drug to permanently lower cholesterol

BioNews

First patient receives genome-editing drug to permanently lower cholesterol

Published 18 July 2022 posted in News

Author

Paige Mumford

Image by Matthew Daniels via the Wellcome Collection. Depicts human cells, showing the stages of cell division.
CC BY 4.0
Image by Matthew Daniels via the Wellcome Collection. Depicts human cells showing the stages of cell division (starting with interphase at the top and progressing anticlockwise, the stages shown are prophase, prometaphase, metaphase, early anaphase, anaphase and telophase).

A novel gene therapy which uses base-editing to lower cholesterol has been given to the first patient in a clinical trial...

A novel gene therapy which uses base editing to lower cholesterol has been given to the first patient in a clinical trial.  

The treatment uses CRISPR base editing to target a single base, deactivating the gene PCSK9 in liver cells, which in some people causes high levels of low-density lipoprotein (LDL) cholesterol. High levels of this 'bad' cholesterol cause arteries to clog and harden over time, resulting in atherosclerotic cardiovascular disease (ASCVD) causing heart attacks and strokes.

'VERVE-101 is a… gene editing medicine… designed to make a single spelling change in liver DNA to permanently turn off a disease-causing gene' said Dr Sekar Kathiresan, CEO of Verve Therapeutics in Massachusetts, who developed the drug. 'The dosing of the first human with such an investigational base editing medicine represents a significant achievement by our team and for the field of gene editing,'

The patient, who is in New Zealand, is part of an ongoing clinical trial on patients with the genetic condition heterozygous familial hypercholesterolemia (HeFH), which causes them to have abnormally high levels of LDL cholesterol that do not respond to lifestyle interventions such as diet and exercise. The clinical trial plans to eventually enrol 40 adult patients with HeFH and evaluate the safety and tolerability of the treatment.

Animal experiments showed the treatment lowered LDL cholesterol by 60 percent, with this change lasting at least a year, and the results could be permanent. However the therapy uses nanoparticles  – which are somewhat toxic – to transport the genetic instructions into the cell; and side effects, such as muscle pain, have been reported by patients taking other drugs that lower PCSK9. Furthermore, while ordinary drugs can be stopped if problems arise, gene therapies are currently irreversible.

Despite these caveats, Verve Therapeutics believes their therapy could eventually be used on millions more, not just HeFH patients, to lower LDL cholesterol and treat ASCVD.

Dr Eric Topol, a cardiologist and researcher at Scripps Research Institute in California, who is not involved in the study commented: 'Of all the different genome editing ongoing in the clinic, this one could have the most profound impact because of the number of people who could benefit.' 

Sources and References

  • 12 July 2022
    Verve Therapeutics
    Verve Therapeutics doses first human with an investigational in vivo base editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia
  • 12 July 2022
    MIT Technology Review
    Edits to a cholesterol gene could stop the biggest killer on earth
  • 13 July 2022
    Pharmaphorum
    Verve starts trials of cholesterol drug in test of base editing technique
  • 12 July 2022
    Biospace
    Verve tests first one and done genome editing treatment for hereditary killer

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

by Michael Limmena

The expression and maturation of a protein that protects cells' elasticity have been mapped with unprecedented clarity and may help in the development of new gene therapies...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
29 April 2022 • 2 minutes read

TALED genome editing approach targets mitochondrial DNA

by James Moore

An approach which significantly improves the ability to modify mitochondrial DNA in living cells has been developed by scientists in South Korea...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
29 October 2021 • 2 minutes read

New method refines CRISPR base editing

by Paige Mumford

Splitting and reconstituting the enzymes used in the base editing method of genome editing may make more controlled changes possible...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
16 July 2021 • 2 minutes read

Prenatal base editing corrects lysosomal storage disease

by Joseph Hawkins

Base editing, a form of genome editing, has been used in preclinical model to correct a lysosomal storage disease known as Hurler syndrome...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 January 2021 • 2 minutes read

Base editing offers hope for child ageing disease

by Anna Wernick

A type of genome editing had been used in mice to treat the symptoms of progeria, a fatal premature ageing disease in children...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« First fertility fraud lawsuit filed in Kentucky

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856